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aDITORIAL COMMENT
epression: Are We
gnoring an Important
omorbidity in Heart Failure?*
hristopher M. O’Connor, MD, FACC,
aren E. Joynt, MD
urham, North Carolina
pproximately 5 million Americans are currently living
ith heart failure (HF), and 550,000 new cases are diag-
osed yearly (1,2). Patients with HF demonstrate a poor
uality of life compared with patients who have other
hronic diseases, scoring poorly on measures of physical
unction, emotional well-being, and overall social function
3,4). Studies have shown that patients with HF have high
ates of depression compared with the general population; in
ddition, depression may confer a negative prognostic im-
act when present in HF patients, with an increased risk of
oth rehospitalization and mortality (5–12).
See page 1542
In this issue of the Journal, Gottlieb et al. (13) report the
esults of a study investigating the prevalence of depression
n a cohort of outpatients with HF. One hundred fifty-five
atients were enrolled, and they completed assessments,
ncluding the Medical Outcomes Study Short Form, the
innesota Living with Heart Failure Questionnaire, and
he Beck Depression Inventory. The authors found that
early one-half (48%) of the patients were depressed.
epressed patients tended to be younger, and women were
ore likely to be depressed than men; white men were more
ikely to be depressed than black men. Depressed patients
cored significantly worse on quality of life measurements
han patients who were not depressed.
This study is important because it extends our knowledge
bout the prevalence of depression in HF to the outpatient
opulation. The authors should be commended for focusing
n this population, about whom considerably less is known
han the inpatient. Furthermore, given that patients spend
he vast majority of their time away from the hospital and
nteract with medical providers primarily at clinic appoint-
ents, this represents a more real-world dataset than one
omposed entirely of inpatients. A limitation to this study,
owever, is that it is a cross-sectional glimpse; we have no
nformation about the course of patients’ depression or
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Medicine, Division of Cardiology, Duke Universitydedical Center, Durham, North Carolinaardiac health and no longitudinal data to correlate depres-
ion with prognosis.
In the past five years, eight studies have reported on the
revalence of depression in HF. Reported prevalence rates
ave ranged from 11% to 25% for outpatients and 35% to
0% for inpatients (5–12). In contrast, 5% to 10% of the
eneral population meets the criteria for depression (14).
he wide range of prevalence rates across studies of HF
atients is likely due to the use of different diagnostic
nstruments and the inclusion of different patient popula-
ions in terms of age, gender, and disease severity. For
xample, depression may be more common in women with
F (5,10,11,15) and in patients with more severe disease or
orse physical symptoms (6,14–16).
What remains largely conjecture, however, is why HF
atients display such a markedly elevated prevalence of
epression. Some researchers believe that the connection
ay lie in shared pathophysiology (for review, see reference
7). Neurohormonal activation (18), rhythm disturbances
19), inflammation (20), and hypercoagulability (21) may all
lay a role in the development, progression, and outcomes
f HF. Interestingly, each of these pathologic states are also
een in depressed patients (22–25). This suggests that
hysiologic states brought on by depression might hasten
he development of HF and worsen prognosis for estab-
ished HF or that a single underlying factor might impact
oth depression and HF. Psychosocial factors may also
ontribute; for example, depression is associated with med-
cal noncompliance, a higher prevalence of smoking, and
ower levels of social support, each of which have been
orrelated with worse outcomes in HF (17).
It is even more unclear why patients with HF and
epression are not more often treated for their depression.
s Gottlieb et al. (13) point out, addressing depression in
F patients represents a prime opportunity to truly improve
hese patients’ quality of life. However, only 7% of the
atients in this study were taking an antidepressant. De-
ression commonly goes undiagnosed; some research sug-
ests that 30% to 50% of cases in the general population are
ever detected by a medical professional (26–29). Patients
ay be unwilling to disclose emotional distress to their
hysicians for fear of being stigmatized with the label of
ental illness because they believe their feelings are part of
heir medical illness or because they don’t want a psychiatric
iagnosis recorded in their medical record (29,30). Physi-
ians may not address depression because they have not
een adequately trained to recognize both typical and
typical depressive symptoms, because of time constraints in
igh-volume settings, or because they do not know how to
est treat the condition. It is also important to recognize the
ifficulty inherent in diagnosing depression in the context of
disease with symptoms that mimic depression, particularly
n the older population (31,32). Heart failure often is
ssociated with fatigue, malaise, and insomnia (3), whereas
epression is characterized by fatigue, insomnia, low mood,
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May 5, 2004:1550–2 Editorial Commentoss of interest in usual activities, weight loss or gain,
eelings of worthlessness, and decreased ability to concen-
rate (29,33). However, it is crucial that both clinicians and
atients realize that the presence of major depression is not
standard part of living with HF. Although feeling upset
bout having a serious disease like HF may be nearly
niversal, major depression is not a normal reaction to
llness and should be recognized as the disabling, chronic,
nd treatable condition that it is.
However, there remains a paucity of information regard-
ng safe and efficacious treatment of depression in patients
ith HF. For example, the recent Enhancing Recovery in
oronary Heart Disease Patients (ENRICHD) trial
howed that nonpharmacologic strategies in the treatment
f depression in patients who suffered a myocardial infarc-
ion may not be efficacious (34), and the Montreal Heart
ttack Readjustment trial (M-HART) suggested that non-
harmacologic treatment of stress in patients who suffered a
yocardial infarction could even be harmful (35). Pharma-
ologic therapy remains controversial as well; tricyclic anti-
epressants are known to affect the cardiac system (36),
hereas selective serotonin reuptake inhibitors have not
een systematically studied in the HF population. The
ecent Sertraline AntiDepressant Heart Attack Random-
zed Trial (SADHART), a randomized trial of sertraline in
epressed patients with acute coronary syndrome, demon-
trated that the treatment of depression can be accom-
lished without increasing worrisome complications or car-
iovascular events (37). Little is known, however, about
reatment in patients with HF. The ongoing Sertraline
ntiDepressant Heart Attack Randomized Trial in Heart
ailure (SADHART-HF), funded by the National Insti-
utes of Mental Health, will give clinicians important data
egarding the safety and efficacy of pharmacologic treatment
or depression in patients with HF.
The increased prevalence of depression seen in patients
ith HF is now well established. What remains is to
etermine why this is the case in the hopes of eventually
eing able to target treatment at the true root of the
roblem. In the meantime, HF patients should be screened
or depression and treated when depression is found to be
resent. In this way, we can help improve patients’ quality of
ife and potentially improve long-term outcomes.
eprint requests and correspondence: Dr. Christopher M.
’Connor, Box 3356 Medical Center, Durham, North Carolina
7710. E-mail: oconn002@mc.duke.edu.
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